Skip to main content

Table 1 Patient characteristics at the time of a refractory response or intolerance to sorafenib treatment

From: Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma

 

Total

group A

group B

group C

P value*

(n = 79)

(n = 44)

(n = 19)

(n = 16)

Age, years

    

0.67

   ≥68

43 (54.4)

23 (52.3)

12 (63.2)

8 (50.0)

 

Gender

    

0.72

   Male

71 (89.9)

39 (88.6)

18 (94.7)

14 (87.5)

 

ECOG performance status

    

0.46

   0

50 (63.3)

29 (65.9)

13 (68.4)

8 (50.0)

 

   1

29 (36.7)

15 (34.1)

6 (31.6)

8 (50.0)

 

hepatitis B surface antigen

0.33

   Positive

27 (34.2)

16 (36.4)

4 (21.1)

7 (43.8)

 

hepatitis C virus antibody

0.82

   Positive

34 (43.0)

20 (45.5)

7 (36.8)

7 (43.8)

 

Child-Pugh class (Child-Pugh score)

0.064

   A (5)

21 (26.6)

11 (25.0)

7 (36.8)

3 (18.8)

 

   A (6)

27 (34.2)

19 (43.2)

6 (31.6)

2 (12.5)

 

   B

31 (39.2)

14 (31.8)

6 (31.6)

11 (68.8)

 

Vascular invasion

    

0.097

   Positive

26 (32.9)

15 (34.1)

3 (15.8)

8 (50.0)

 

Extra-hepatic spread

    

0.62

   Positive

43 (54.4)

22 (50.0)

12 (63.2)

9 (56.3)

 

AFP a, n (%)

    

0.87

   ≥400 ng/mL

29 (36.7)

17 (38.6)

6 (31.6)

6 (37.5)

 

Cause of failure of sorafenib treamtnet

0.080

   Tumor progression

60 (75.9)

37 (84.1)

14 (73.7)

9 (56.3)

 

   Adverse effect

19 (24.1)

7 (15.9)

5 (26.3)

7 (43.8)

 

Time to treatment failure of sorafenib, months

0.059

   <2.56

39 (49.4)

20 (45.5)

7 (36.8)

12 (75.0)

 

   ≥2.56

40 (50.6)

24 (54.5)

12 (63.2)

4 (25.0)

 
  1. a AFP α-fetoprotein
  2. *chi-squared test